The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive ...
Hosted on MSN
BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks under $100. On October 9, BofA raised the firm’s price target on Teva to $24 from $22, while keeping a Buy rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results